At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,653 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multi-center, Non-interventional Observational Study to Evaluate the Safety and Effectiveness of MabThera® (Rituximab) Within the First 6 Months (in Case of Re-therapy the First 12 Months) of Treatment in Patients With Severe Active Rheumatoid Arthritis in Routine Care
In Brief
An observational study evaluating Rituximab for Rheumatoid Arthritis. Completed, enrolled 1,653 participants across 1 site.
Detailed Summary
This prospective observational study aims to evaluate safety, application and onset of effect of rituximab in clinical routine treatment of severe active rheumatoid arthritis during the first 6 months (in case of re-therapy: 12 months).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedFeb 2010
Primary CompletionOct 2014
TodayJul 2026
First PostedFeb 19, 2010
Enrollment StartJan 1, 2010
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 16.4 years ago
Interventions
Rituximabdrug
As prescribed by physician